Lightspeed Venture Partners, a venture capital firm, led a $101m Series A financing round in Seismic Therapeutic, a biotechnology company advancing machine learning for immunology drug development, with participation from Polaris Partners, Boxer Capital and Samsara Biocapital. “We are leading the next generation of immunology drug development with Seismic’s platform. By integrating machine learning throughout the biologics drug discovery process, we are powered by a systematic and programmable approach to design superior biologics from initial discovery and therapeutic design through to manufacturability,” Jo Viney, Seismic Therapeutic Founder, President and CEO.